A detailed history of Schroder Investment Management Group transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Schroder Investment Management Group holds 205,779 shares of VRTX stock, worth $92.9 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
205,779
Previous 228,819 10.07%
Holding current value
$92.9 Million
Previous $107 Million 10.77%
% of portfolio
0.1%
Previous 0.12%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $10.6 Million - $11.7 Million
-23,040 Reduced 10.07%
205,779 $95.7 Million
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $8.06 Million - $9.97 Million
20,531 Added 9.86%
228,819 $107 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $10.1 Million - $11 Million
-24,692 Reduced 10.6%
208,288 $87.1 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $13.6 Million - $16.3 Million
39,712 Added 20.55%
232,980 $94.8 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $569,495 - $610,382
-1,684 Reduced 0.86%
193,268 $67.2 Million
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $5.24 Million - $5.86 Million
16,657 Added 9.34%
194,952 $68.6 Million
Q1 2023

May 11, 2023

SELL
$283.23 - $323.1 $6.11 Million - $6.97 Million
-21,566 Reduced 10.79%
178,295 $56.2 Million
Q4 2022

Feb 10, 2023

BUY
$285.76 - $321.48 $26 Million - $29.2 Million
90,908 Added 83.44%
199,861 $57.7 Million
Q3 2022

Nov 10, 2022

BUY
$273.83 - $305.53 $14.9 Million - $16.7 Million
54,563 Added 100.32%
108,953 $31.5 Million
Q2 2022

Aug 11, 2022

SELL
$234.96 - $292.55 $1.61 Million - $2.01 Million
-6,863 Reduced 11.2%
54,390 $15.2 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $3.4 Million - $4.01 Million
15,359 Added 33.47%
61,253 $15.7 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $227,457 - $287,133
-1,285 Reduced 2.72%
45,894 $10.1 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $524,398 - $586,844
2,891 Added 6.53%
47,179 $8.56 Million
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $3.44 Million - $4.05 Million
18,328 Added 70.6%
44,288 $8.93 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $83,015 - $96,765
401 Added 1.57%
25,960 $5.58 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $309,065 - $412,202
-1,493 Reduced 5.52%
25,559 $6.04 Million
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $14 Million - $16.6 Million
-54,791 Reduced 66.95%
27,052 $7.06 Million
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $16.1 Million - $21.1 Million
71,250 Added 672.61%
81,843 $23.8 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $290,865 - $360,811
-1,456 Reduced 12.08%
10,593 $2.7 Million
Q4 2019

Feb 11, 2020

SELL
$166.71 - $223.91 $6.48 Million - $8.71 Million
-38,880 Reduced 76.34%
12,049 $2.64 Million
Q3 2019

Nov 12, 2019

BUY
$166.23 - $187.09 $7.71 Million - $8.68 Million
46,382 Added 1020.06%
50,929 $8.49 Million
Q2 2019

Aug 08, 2019

SELL
$164.61 - $190.37 $4.9 Million - $5.67 Million
-29,775 Reduced 86.75%
4,547 $834,000
Q1 2019

May 14, 2019

SELL
$163.73 - $194.7 $8,350 - $9,929
-51 Reduced 0.15%
34,322 $6.31 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $112,109 - $141,850
738 Added 2.19%
34,373 $5.7 Million
Q3 2018

Nov 13, 2018

BUY
$167.73 - $192.74 $1.06 Million - $1.22 Million
6,326 Added 23.16%
33,635 $6.48 Million
Q2 2018

Aug 13, 2018

BUY
$145.72 - $169.96 $269,436 - $314,256
1,849 Added 7.26%
27,309 $4.03 Million
Q1 2018

May 11, 2018

BUY
$151.6 - $177.13 $197,080 - $230,269
1,300 Added 5.38%
25,460 $4.15 Million
Q3 2017

Nov 09, 2017

BUY
$148.13 - $162.24 $3.58 Million - $3.92 Million
24,160
24,160 $3.62 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Schroder Investment Management Group Portfolio

Follow Schroder Investment Management Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.